WARS1, TYMP and GBP1 display a distinctive microcirculation pattern by immunohistochemistry during antibody-mediated rejection in kidney transplantation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 11 2022
Historique:
received: 12 09 2022
accepted: 25 10 2022
entrez: 9 11 2022
pubmed: 10 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

Antibody-mediated rejection (ABMR) is the leading cause of allograft failure in kidney transplantation. Defined by the Banff classification, its gold standard diagnosis remains a challenge, with limited inter-observer reproducibility of the histological scores and efficient immunomarker availability. We performed an immunohistochemical analysis of 3 interferon-related proteins, WARS1, TYMP and GBP1 in a cohort of kidney allograft biopsies including 17 ABMR cases and 37 other common graft injuries. Slides were interpreted, for an ABMR diagnosis, by four blinded nephropathologists and by a deep learning framework using convolutional neural networks. Pathologists identified a distinctive microcirculation staining pattern in ABMR with all three antibodies, displaying promising diagnostic performances and a substantial reproducibility. The deep learning analysis supported the microcirculation staining pattern and achieved similar diagnostic performance from internal validation, with a mean area under the receiver operating characteristic curve of 0.89 (± 0.02) for WARS1, 0.80 (± 0.04) for TYMP and 0.89 (± 0.04) for GBP1. The glomerulitis and peritubular capillaritis scores, the hallmarks of histological ABMR, were the most highly correlated Banff scores with the deep learning output, whatever the C4d status. These novel immunomarkers combined with a CNN framework could help mitigate current challenges in ABMR diagnosis and should be assessed in larger cohorts.

Identifiants

pubmed: 36352007
doi: 10.1038/s41598-022-23078-z
pii: 10.1038/s41598-022-23078-z
pmc: PMC9646783
doi:

Substances chimiques

Antibodies 0
GBP1 protein, human 0
GTP-Binding Proteins EC 3.6.1.-
TYMP protein, human EC 2.4.2.4
Thymidine Phosphorylase EC 2.4.2.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19094

Informations de copyright

© 2022. The Author(s).

Références

Nat Med. 2018 Oct;24(10):1559-1567
pubmed: 30224757
Nat Cancer. 2020 Aug;1(8):789-799
pubmed: 33763651
J Am Soc Nephrol. 2019 Apr;30(4):692-709
pubmed: 30850439
Am J Transplant. 2011 Mar;11(3):450-62
pubmed: 20973913
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Am J Transplant. 2017 Jan;17(1):28-41
pubmed: 27862883
Am J Transplant. 2022 Aug;22(8):1976-1991
pubmed: 35575435
Transpl Int. 2019 Feb;32(2):173-183
pubmed: 30179275
Am J Transplant. 2020 Sep;20(9):2318-2331
pubmed: 32463180
PLoS Med. 2019 Jan 24;16(1):e1002730
pubmed: 30677016
Front Immunol. 2021 Sep 27;12:718122
pubmed: 34646262
Kidney Int. 2019 Jul;96(1):189-201
pubmed: 31005275
Nat Med. 2019 Jul;25(7):1054-1056
pubmed: 31160815
Am J Transplant. 2009 Oct;9(10):2312-23
pubmed: 19681822
Biomedicines. 2022 Feb 28;10(3):
pubmed: 35327371
Am J Transplant. 2012 Feb;12(2):388-99
pubmed: 22081892
Am J Transplant. 2008 Apr;8(4):819-25
pubmed: 18261174
Am J Pathol. 2022 Oct;192(10):1418-1432
pubmed: 35843265
Nat Commun. 2019 Nov 25;10(1):5350
pubmed: 31767837
Lancet Digit Health. 2022 Jan;4(1):e18-e26
pubmed: 34794930
Kidney Int. 2022 Feb;101(2):288-298
pubmed: 34757124
Sci Rep. 2019 Mar 26;9(1):5123
pubmed: 30914690
Mod Pathol. 2020 Aug;33(8):1626-1634
pubmed: 32218521
N Engl J Med. 2018 Sep 20;379(12):1150-1160
pubmed: 30231232
Sci Rep. 2020 Jan 30;10(1):1504
pubmed: 32001752
J Am Soc Nephrol. 2018 Aug;29(8):2069-2080
pubmed: 29980650
Am J Transplant. 2014 Feb;14(2):272-83
pubmed: 24472190
Am J Transplant. 2018 Apr;18(4):785-795
pubmed: 29178397
Nephrology (Carlton). 2015 Jul;20(7):467-73
pubmed: 25726938

Auteurs

Bertrand Chauveau (B)

Department of Pathology, Pellegrin Hospital, Bordeaux University Hospital, Place Amélie Raba Léon, 33000, Bordeaux, France. bertrand.chauveau@chu-bordeaux.fr.
University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 Rue Léo Saignat, 33000, Bordeaux, France. bertrand.chauveau@chu-bordeaux.fr.

Antoine Garric (A)

University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 Rue Léo Saignat, 33000, Bordeaux, France.
Department of Nephrology, Transplantation Dialysis, Apheresis, Pellegrin Hospital, Bordeaux University Hospital, Place Amélie Raba Léon, 33000, Bordeaux, France.

Sylvaine Di Tommaso (S)

University of Bordeaux, Oncoprot Platform, TBM-Core US 005, 33000, Bordeaux, France.
University of Bordeaux, INSERM UMR1312, BoRdeaux Institute of onCology (BRIC), 33000, Bordeaux, France.

Anne-Aurélie Raymond (AA)

University of Bordeaux, Oncoprot Platform, TBM-Core US 005, 33000, Bordeaux, France.
University of Bordeaux, INSERM UMR1312, BoRdeaux Institute of onCology (BRIC), 33000, Bordeaux, France.

Jonathan Visentin (J)

University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 Rue Léo Saignat, 33000, Bordeaux, France.
Laboratory of Immunology and Immunogenetics, Pellegrin Hospital, Bordeaux University Hospital, Place Amélie Raba Léon, 33000, Bordeaux, France.

Agathe Vermorel (A)

Department of Nephrology, Transplantation Dialysis, Apheresis, Pellegrin Hospital, Bordeaux University Hospital, Place Amélie Raba Léon, 33000, Bordeaux, France.

Nathalie Dugot-Senant (N)

University of Bordeaux, Platform of Histopathology, TBMCore - INSERM US005 - CNRS UAR 3427, 33000, Bordeaux, France.

Julie Déchanet-Merville (J)

University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 Rue Léo Saignat, 33000, Bordeaux, France.

Jean-Paul Duong Van Huyen (JP)

INSERM U970, Paris, France.
Department of Pathology, Necker Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.

Marion Rabant (M)

Department of Pathology, Necker Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France.
INSERM U1151, Paris, France.

Lionel Couzi (L)

University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 Rue Léo Saignat, 33000, Bordeaux, France.
Department of Nephrology, Transplantation Dialysis, Apheresis, Pellegrin Hospital, Bordeaux University Hospital, Place Amélie Raba Léon, 33000, Bordeaux, France.

Frédéric Saltel (F)

University of Bordeaux, Oncoprot Platform, TBM-Core US 005, 33000, Bordeaux, France.
University of Bordeaux, INSERM UMR1312, BoRdeaux Institute of onCology (BRIC), 33000, Bordeaux, France.

Pierre Merville (P)

University of Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 Rue Léo Saignat, 33000, Bordeaux, France.
Department of Nephrology, Transplantation Dialysis, Apheresis, Pellegrin Hospital, Bordeaux University Hospital, Place Amélie Raba Léon, 33000, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH